John Michael Kane MD
Psychopharmacology
Professor, The Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research. Vice President, Behavioral Health Services, Northwell Health. Chairman, Department of Psychiatry, The Zucker Hillside Hospital. Chair & Professor, Psychiatry, Hofstra Northwell School of Medicine. Professor, Molecular Medicine, Hofstra Northwell School of Medicine.
Join to view full profile
75-59 263rd StreetKaufman Building, Suite 103Glen Oaks, NY 11004
Phone+1 718-470-8141
Dr. Kane is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Kane is a psychiatrist in Glen Oaks, NY and is affiliated with multiple hospitals in the area, including Long Island Jewish Medical Center, Glen Cove Hospital, and The Zucker Hillside Hospital. He received his medical degree from NYU Grossman School of Medicine and has been in practice 46 years. He specializes in psychopharmacology and is experienced in bipolar disorder, depression, schizophrenia, mood disorders, and anxiety disorders.
Education & Training
Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalResidency, Psychiatry, 1971 - 1975
New York University School of MedicineClass of 1971
Certifications & Licensure
NY State Medical License 1972 - 2027
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
Publications & Presentations
PubMed
- ACES: ascertaining diagnosis classification with elicited speech in individuals with heterogeneous, comorbid psychiatric disorders.Sunny X Tang, Jiefei Li, Katharina Brosch, Nizar Massouh, Sandy Yin
Psychiatry Research. 2026-08-14 - Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia.Christoph U Correll, John M Kane, Mark Suett, Kelli R Franzenburg, Rolf Hansen
Journal of Psychiatric Research. 2026-08-06 - A Proposed Expansion of the Definition of Treatment-Resistant Schizophrenia.Jose M Rubio, John M Kane
The American Journal of Psychiatry. 2026-08-01
Journal Articles
- Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase SchizophreniaJohn M Kane, Eric D Achtyes, Delbert G Robinson, JAMA Psychiatry
- Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel DatasetJohn Kane, MD, JMIR Medical Education
- Disturbing Lack of Early Intervention Studies in Bipolar Disorder—ReplyJohn Kane, MD, JAMA
Authored Content
- Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase SchizophreniaJuly 2020
- Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel DatasetDecember 2018
Press Mentions
International Schizophrenia Experts Develop Consensus Criteria for RelapseOctober 9th, 2025- Sunny Tang, MD: Decoding Speech Patterns to Improve Psychiatric CareMay 15th, 2025
- Teva to Present Data Demonstrating UZEDYtm (Risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association's 2023 Annual MeetingMay 22nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
